End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk of development and treatment.
about
Mycophenolate mofetil for liver-transplanted patientsManagement of immunosuppressant agents following liver transplantation: Less is moreHepatorenal syndrome: Update on diagnosis and treatmentRenal dysfunction in liver transplant recipients: evaluation of the critical issuesOutcomes of liver transplantation in patients with hepatorenal syndromeProtecting the Kidney in Liver Transplant Candidates: Practice-Based Recommendations From the American Society of Transplantation Liver and Intestine Community of Practice.The benefit of sirolimus maintenance immunosuppression and rabbit antithymocyte globulin induction in liver transplant recipients that develop acute kidney injury in the early postoperative periodConversion to sirolimus immunosuppression in liver transplantation recipients with hepatocellular carcinoma: Report of an initial experienceReduced-dose tacrolimus with mycophenolate mofetil vs. standard-dose tacrolimus in liver transplantation: a randomized study.A therapeutic exploratory study to determine the efficacy and safety of calcineurin-inhibitor-free de-novo immunosuppression after liver transplantation: CILT.A comprehensive review of immunosuppression used for liver transplantation.Study protocol: a pilot study to determine the safety and efficacy of induction-therapy, de novo MPA and delayed mTOR-inhibition in liver transplant recipients with impaired renal function. PATRON-study.Predictors of renal function recovery among patients undergoing renal replacement therapy following orthotopic liver transplantationUse of sirolimus in liver transplant recipients with renal insufficiency: a systematic review and meta-analysisBelatacept-based immunosuppression in de novo liver transplant recipients: 1-year experience from a phase II randomized study.Endothelial nitric oxide synthase gene variation associated with chronic kidney disease after liver transplantRisk factors for chronic anemia in pediatric orthotopic liver transplantation: analysis of data from the SPLIT registry.Chronic kidney disease and associated mortality after liver transplantation--a time-dependent analysis using measured glomerular filtration rate.Post-liver transplant acute renal failure: factors predicting development of end-stage renal disease.Identification of patients best suited for combined liver-kidney transplantation: part II.An analysis of tacrolimus-related complications in the first 30 days after liver transplantation.Long-term management of the successful adult liver transplant: 2012 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation.Equal 3-Year Outcomes for Kidney Transplantation Alone in HCV-Positive Patients With CirrhosisRisk factors for end-stage kidney disease after pediatric liver transplantation.Clinical and plasma proteomic markers correlating with chronic kidney disease after liver transplantationCongenital hepatic fibrosis and autosomal recessive polycystic kidney disease.Clinical Risk Scoring Models for Prediction of Acute Kidney Injury after Living Donor Liver Transplantation: A Retrospective Observational Study.Prophylaxis of chronic kidney disease after liver transplantation--experience from west ChinaRenal impairment after liver transplantation - a pilot trial of calcineurin inhibitor-free vs. calcineurin inhibitor sparing immunosuppression in patients with mildly impaired renal function after liver transplantationChronic kidney disease stage progression in liver transplant recipients.Chronic Kidney Disease and Related Long-Term Complications After Liver Transplantation.Review article: current management of renal dysfunction in the cirrhotic patient.Recipient survival and graft survival are not diminished by simultaneous liver-kidney transplantation: an analysis of the united network for organ sharing databaseLiver transplantation as ultimate tool to treat portal hypertension.Comparing 10-yr renal outcomes in deceased donor and living donor liver transplants.Chronic kidney disease after liver, cardiac, lung, heart-lung, and hematopoietic stem cell transplant.Effect of long-term tacrolimus immunosuppression on renal function in liver transplant recipients.Daclizumab induction therapy in liver transplant recipients with renal insufficiencyNative kidney function following liver transplantation using calcineurin inhibitors: single-center analysis with 20 years of follow-up.Acute renal failure and chronic kidney disease following liver transplantation.
P2860
Q24242476-56F54015-410D-4150-9FDD-47169090F6EAQ26770033-AE7292D6-6B66-4383-8BA0-0EF0137AC241Q26777608-A87284EF-B8B0-41E0-802F-F593F65B8DAFQ27026577-D31B2A9F-3D4B-4602-A3A0-D6A4303603B2Q28068506-C424CAA8-11AB-4942-B2EC-7B622683C685Q30251763-62E573A6-A019-4099-95B7-D07C17E41502Q30300206-BA1297F4-5DBA-4411-9FA7-97AADD0DCC88Q33371289-C0060ECB-E563-479D-9BC0-7804898BA1FFQ33394798-348126AD-6C7B-4137-83A4-6F68705C0ECDQ33551422-FFC23411-938B-4D7E-91D2-62DC68596194Q33602527-3BFED6A1-DFCE-43FC-9D09-24C3BC05B364Q33692413-0B8D3904-E8BB-4601-9A6F-BA5E2EDBA806Q33757393-34906357-551B-4AEC-BB6B-4826CAD18662Q34034891-EB4852CD-5113-4971-959C-963E46C8B790Q34074790-4359E4E8-CE91-42DB-82AD-656034E9003FQ34098493-AC6F2EE6-8CF3-4CDA-BA8E-FDB362F9193CQ34107643-CD083FF5-F095-466B-AA65-C70DEFA87FEAQ34160624-88383B4E-D173-4347-A27B-5D05E679B7CAQ34316390-8E17A2AF-C306-49C8-828E-9151BA5C6B13Q34575149-A7D20642-3544-43C4-8916-E1E6C9D90152Q34628163-4E9A962C-FBF2-4D7A-A0ED-E6B6C5D64C82Q34646976-BD2FA278-267C-4427-8AF2-9871E7C20830Q34993200-33303BEE-CC63-44E3-9BE5-7326DC0C4CA5Q35096234-C083EF79-4AC8-4C26-8523-39A5A83CDCC6Q35194548-5BDA2E30-506E-41E1-931D-7C7BA45D7AAEQ35206399-B6368603-9A1B-4B2B-BF79-4F26B8619E65Q35753829-8A65B44F-47FF-42F3-860D-5E45E2A9C28DQ35813528-9A7CCD22-77CC-41D4-8B0E-DD79F554BD8CQ35959103-33EFD101-04D8-4C5F-885A-993B6A4DF915Q35985673-DB11B401-4B39-4349-9614-258C9F98D42EQ36015474-F727E1A1-17B1-455F-A6C0-51946B03E891Q36090748-B8B469BC-9C0C-4BE0-B039-D4D94666AD08Q36117136-1033BC08-61F5-40CE-91E6-CCC98DF83D8BQ36141452-5FF80D24-A090-490A-A7ED-C7CA4F77E245Q36470110-976494F6-4012-4D7E-B593-B63C03EB3F7FQ36585425-16D4D2F3-26EC-42A0-8E0B-92FD5D7EBD49Q36603215-3BF38DEB-CB75-4535-9A15-951B041B2D96Q36710213-AA5A15BD-3A49-40F4-8335-564987DA6CECQ36755975-C78F50B2-21C5-4D0F-879C-75A6E9699E2CQ36952503-C287190E-DE19-427E-8AC0-7A393EFCFAC8
P2860
End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk of development and treatment.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
End-stage renal disease (ESRD) ...... of development and treatment.
@en
type
label
End-stage renal disease (ESRD) ...... of development and treatment.
@en
prefLabel
End-stage renal disease (ESRD) ...... of development and treatment.
@en
P2093
P1433
P1476
End-stage renal disease (ESRD) ...... of development and treatment.
@en
P2093
Goldstein RM
Klintmalm GB
P304
P356
10.1097/00007890-200112270-00012
P577
2001-12-01T00:00:00Z